Organoid & Organ-on-Chip Patents: Who Leads, Where the Gaps Are 2026
- 33.6% concentration. The top 5 of 899 records in scope sit with a small cluster of hospital and university assignees, but filing has gone flat since a 2023 peak of 95.
- Liver organoid priority art still dominates citations. The most-cited record in the set, WO2012014076A2, anchors downstream claims on liver organoid culture methods filed more than a decade ago.
- Momentum has stalled at the top. Several of the leading assignees show zero filings in the latest year, some down 100% year-on-year, opening room for new entrants in readout and validation claims.
What this patent set covers
This landscape covers 899 patent records filed between 2015 and mid-2026 that combine organoid, organ-on-a-chip or microphysiological system terminology with claims touching differentiation protocols, reproducibility, vascularization, readout integration or regulatory acceptance for toxicology. The scope spans C12N5 cell-culture classifications alongside B01L3 lab-apparatus and C12M3 bioreactor filings, so it captures both the biological method claims and the hardware built to run them.
Filing volume rose through the late 2010s, peaked in 2023 at 95 records, and has since flattened — the most recent year is undercounted because publication typically lags filing by around 18 months. Reading the trend as flat-to-declining rather than as an active decline is the safer interpretation until later filings clear the pipeline.
Filing trends and technology composition
Two views of the same 899-record set: how filing volume has moved year over year, and how records distribute across the IPC subclasses they carry.
A 2023 peak followed by a plateau
Filings climbed from 77 in 2017 to a peak of 95 in 2023, sat at 73 by the 2022 midpoint, and have not exceeded that peak since — a pattern consistent with a maturing claim space rather than one still opening up.
C12N dominates; hardware and readout classes trail
C12N (microorganisms and genetic engineering) appears on 89.3% of the 899 records, far ahead of A61K medicinal preparations at 26.4% and C12M bioreactor apparatus at 22.6%. G01N material analysis and testing sits at 17.1% and B01L lab apparatus at just 5.2% — the smallest of the eight classes tracked, and a signal that instrumentation and readout claims are comparatively thin against the biology.
Shares are the percentage of the 899 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Organoids and Organ-on-Chip Models with Eureka
This page is one run against one query. Ask Eureka your own question about organoids and organ-on-chip models and every answer comes back with the patent numbers behind it.
Try EurekaThe filings shaping this space
Biosensor-integrated multi-organ-on-a-chip system for real-time and long-term monitoring of organoid function
A PDMS-based multi-organ-on-a-chip platform with a multi-organoid chamber, automated media exchange, and integrated aptamer-based protein and environmental sensors, circulated by a peristaltic pump for continuous, long-term monitoring of organoid function.Filed by Wake Forest University Health Sciences, published December 2025 — one of the most recent entrants combining hardware, sensing and organoid biology in a single claim set.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2012014076A2 | Liver organoid, uses thereof and culture method for obtaining them | 143 |
| 2 | US20130189327A1 | Liver organoid, uses thereof and culture method for obtaining them | 130 |
| 3 | WO2014159356A1 | Compositions and methods for epithelial stem cell expansion and culture | 123 |
| 4 | WO1993008850A1 | Prevascularized polymeric implants for organ transplantation | 108 |
| 5 | WO2015183920A2 | Methods and systems for converting precursor cells into gastric tissues through directed differentiation | 87 |
| 6 | US20030129751A1 | Tissue-engineered organs | 87 |
| 7 | US20170240866A1 | Methods and systems for converting precursor cells into gastric tissues through directed differentiation | 63 |
| 8 | US20140220555A1 | In vitro microphysiological system for high throughput 3D tissue organization and biological function | 63 |
| 9 | WO2013056019A1 | In vitro microphysiological system for high throughput 3D tissue organization and biological function | 60 |
| 10 | WO2017205511A1 | Compositions and methods for organoid generation and disease modeling | 59 |
Citation counts are drawn from within this searched corpus and favour older filings; treat them as a measure of influence on subsequent claims, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for filing strategy
Read together, the concentration figures, the citation table and the flat recent trend point to a field where the founding biology is well claimed but the instrumentation layer built around it is not.
A narrow leadership group, not a crowded field
The top 5 of 899 records account for 33.6%, and the top 10 for 44.7% — meaningful concentration, but it leaves more than half the corpus spread across a long tail of single- and few-filing entrants, mostly hospitals and universities.
Liver organoid method claims sit on old, heavily cited art
WO2012014076A2 and its US counterpart on liver organoid culture methods carry the highest citation counts in the set, meaning any new liver-organoid differentiation claim is likely to be examined against this prior art first.
Leaders have gone quiet at the same time volume flattened
Multiple of the assignees with the largest historical portfolios show zero filings in the most recent year, several down 100% year-on-year — consistent with the overall plateau but worth confirming against the 18-month publication lag before reading it as retreat.
Hardware and readout claims are thin relative to biology
C12N appears on 89.3% of records while B01L lab apparatus sits at only 5.2% — the biological method space is dense, but the physical readout and lab-apparatus layer that integrates with it is comparatively open.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to organoids and organ-on-chip models, with the prior art for and against each one.
Who holds the ground, and where filing has slowed
The ranking covers 100 companies and institutions counted by record, dominated by academic medical centers and research universities rather than industrial manufacturers — a marker of a field still moving from bench to platform.
One institution well ahead of the field
The leading assignee holds 135 records, close to double the fifth-place holder at 30 and far ahead of tenth place at 15 — a steep drop-off rather than a gradual one.
A small number of institutions co-file repeatedly
The strongest co-assignee pair recurs 33 times, well ahead of the next pairs at 10 and 6 — evidence of a durable, specific research partnership rather than one-off joint filings.
US and Europe lead filing venues, PCT close behind
The United States receives the most filings at 238, followed by the European Patent Office at 184 and WIPO's PCT route at 172 — China trails at 39, suggesting protection strategy still centers on US and European markets first.
| Assignee | Recent year | YoY |
|---|---|---|
| Children's Hospital Medical Center (Cincinnati) | 0 | -100% |
| Massachusetts Institute of Technology | 0 | — |
| Royal Netherlands Academy of Arts and Sciences | 0 | -100% |
| The Brigham and Women's Hospital | 0 | -100% |
| TissUse GmbH | 0 | — |
| President and Fellows of Harvard College | 0 | -100% |
| Keio University | 0 | — |
| The Regents of the University of California | 0 | -100% |
Where to take this analysis
The trends here point to next questions rather than final answers — each one is worth running against the full record set before committing a filing strategy.
Check the 18-month lag before reading the plateau as decline
The apparent flattening after 2023 partly reflects publication lag; pulling the most recent filing-date records specifically, rather than publication-date records, gives a truer read on 2024-2026 activity.
Explore filing trends in EurekaMap claim language in the B01L and readout-integration space
With only 5.2% of records carrying B01L classification against 89.3% for C12N, a claim-by-claim read of the hardware layer is likely to surface open drafting room faster than another pass through the biology.
Run a claim comparison in EurekaWatch the quiet leaders for reactivation
Several top assignees show zero filings in the latest year; tracking their grant activity and litigation history will show whether they are consolidating existing claims or genuinely stepping back.
Track assignee activity in EurekaCommon questions on organoid and organ-on-chip patents
The ranked leader in this 899-record dataset holds 135 records, well ahead of the fifth-ranked assignee at 30 and the tenth at 15. Leadership is concentrated among academic medical centers and research universities rather than industrial manufacturers, reflecting the field's continued roots in bench research. The top 5 assignees together account for 33.6% of all 899 records, so while there is a clear leader, more than half the corpus is held by a long tail of smaller filers.
Filing volume rose from 77 records in 2017 to a peak of 95 in 2023, but has not exceeded that peak since, and the midpoint year of 2022 sat at 73 — a pattern that reads as flat to declining rather than accelerating. The most recent year's count is understated because publication typically lags filing by about 18 months, so the true 2025-2026 picture will only become clear as those filings publish. Several of the historically largest filers also show zero filings in the latest year, reinforcing the plateau reading.
Organoid biology claims cluster overwhelmingly in C12N (microorganisms and genetic engineering), which appears on 89.3% of the 899 records in scope. Hardware and lab-apparatus claims fall mainly under B01L, present on just 5.2% of records, and C12M bioreactor apparatus at 22.6%. Because a single record can carry multiple IPC classes, these figures do not sum to 100%, but the gap between the biology and hardware classes is a useful signal of where claim space is comparatively open.
WO2012014076A2, covering liver organoid methods and their uses, is the most-cited record in this dataset at 143 citations, with its US counterpart US20130189327A1 close behind at 130. High citation counts within a searched corpus tend to favour older filings simply because they have had more time to accumulate citing art, so this reflects foundational influence on liver organoid method claims rather than current commercial dominance. Anyone drafting new liver-organoid differentiation claims should expect this filing to surface in prior-art searches.
The clearest gaps sit in the readout and instrumentation layer rather than the biology: B01L lab-apparatus classification covers only 5.2% of the 899 records, far below the 89.3% carrying C12N biology classes. Sub-areas like integrated biosensor readout, standardized reproducibility protocols across organoid batches, and regulatory-grade toxicology validation packages show comparatively light claim density. Filing activity from several top assignees has also gone quiet in the most recent year, which can either mean consolidation of existing claims or a genuine opening for new entrants.
Research Organoids and Organ-on-Chip Models in depth with Eureka
Go past this page: query the whole organoids and organ-on-chip models corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.